JP2004508304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508304A5 JP2004508304A5 JP2002523445A JP2002523445A JP2004508304A5 JP 2004508304 A5 JP2004508304 A5 JP 2004508304A5 JP 2002523445 A JP2002523445 A JP 2002523445A JP 2002523445 A JP2002523445 A JP 2002523445A JP 2004508304 A5 JP2004508304 A5 JP 2004508304A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- alkenyl
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 heterocyclylamino Chemical group 0.000 claims description 142
- 150000001875 compounds Chemical class 0.000 claims description 37
- 125000003342 alkenyl group Chemical group 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 125000000304 alkynyl group Chemical group 0.000 claims description 24
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 102100023724 Melanocortin receptor 4 Human genes 0.000 claims description 4
- 101710085775 Melanocortin receptor 4 Proteins 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000000033 alkoxyamino group Chemical group 0.000 claims 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000005241 heteroarylamino group Chemical group 0.000 claims 3
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 150000004678 hydrides Chemical class 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 106
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 55
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 48
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 34
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 29
- 229920002554 vinyl polymer Polymers 0.000 description 29
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 7
- 150000003857 carboxamides Chemical class 0.000 description 7
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 6
- 150000002513 isocyanates Chemical class 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 5
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 3
- 125000004352 2-phenylcyclohexyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 3
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 3
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- GJMPSRSMBJLKKB-UHFFFAOYSA-N 3-methylphenylacetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1 GJMPSRSMBJLKKB-UHFFFAOYSA-N 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940117957 triethanolamine hydrochloride Drugs 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XOJSCPAYGRSALL-FTJBHMTQSA-N 4-[[N'-[(1S,2R)-2-aminocyclohexyl]-N-cyclohexylcarbamimidoyl]amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound N[C@H]1[C@H](CCCC1)N/C(=N\C1CCCCC1)/NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl XOJSCPAYGRSALL-FTJBHMTQSA-N 0.000 description 1
- JUAJTUBIUYDYSM-UHFFFAOYSA-N 4-[[N-(2-adamantyl)-C-(3,5-dimethylpiperazin-1-yl)carbonimidoyl]amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\C1C(C2)CC3CC2CC1C3 JUAJTUBIUYDYSM-UHFFFAOYSA-N 0.000 description 1
- SCGJOCKIRPQRCE-UHFFFAOYSA-N 4-[[N-(3-aminocyclohexyl)-N'-cyclohexylcarbamimidoyl]amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound NC1CC(CCC1)N/C(=N\C1CCCCC1)/NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl SCGJOCKIRPQRCE-UHFFFAOYSA-N 0.000 description 1
- ULUAKWCUUHPYFB-UHFFFAOYSA-N 4-[[N-(4-tert-butylcyclohexyl)-C-(3,5-dimethylpiperazin-1-yl)carbonimidoyl]amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\C1CCC(C(C)(C)C)CC1 ULUAKWCUUHPYFB-UHFFFAOYSA-N 0.000 description 1
- USQKRZFURYWKLE-NRFANRHFSA-N 4-[[N-cyclooctyl-C-[(3S)-3-methylpiperazin-1-yl]carbonimidoyl]amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound C[C@H]1CN(CCN1)C(NC1=CC=C(C=C1)C(=O)NCCC1=C(Cl)C=C(Cl)C=C1)=N/C1CCCCCCC1 USQKRZFURYWKLE-NRFANRHFSA-N 0.000 description 1
- GXFNBCKBVWMOEW-VTYYSHTASA-N 4-[[n-(2-adamantyl)-c-[(3s)-3-methylpiperazin-1-yl]carbonimidoyl]amino]-n-[2-(2,4-dichlorophenyl)ethyl]benzamide Chemical compound C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\C1C(C2)CC3CC2CC1C3 GXFNBCKBVWMOEW-VTYYSHTASA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- UOHUTMGUEZCFRD-ULJHMMPZSA-N C1(NCCC1)\C=C(/N1CCNCC1)\NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCC1)\C=C(/N1CCNCC1)\NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl UOHUTMGUEZCFRD-ULJHMMPZSA-N 0.000 description 1
- KNLMHWSCNOCXCX-UHFFFAOYSA-N C1(NCCCC1)C=C(/N(CC1=CC=CC=C1)CC=1NC=CN1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 Chemical compound C1(NCCCC1)C=C(/N(CC1=CC=CC=C1)CC=1NC=CN1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 KNLMHWSCNOCXCX-UHFFFAOYSA-N 0.000 description 1
- RLUSOBKCYXAKSI-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CC(NCC1)=O)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CC(NCC1)=O)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl RLUSOBKCYXAKSI-UHFFFAOYSA-N 0.000 description 1
- HSRXIQJMZZNUGP-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CC(NCC1)C1=CC=CC=C1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CC(NCC1)C1=CC=CC=C1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl HSRXIQJMZZNUGP-UHFFFAOYSA-N 0.000 description 1
- DFMVFAKJGQHCEJ-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CCN(CC1)C(=O)C=1OC=CC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CCN(CC1)C(=O)C=1OC=CC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl DFMVFAKJGQHCEJ-UHFFFAOYSA-N 0.000 description 1
- PPKQTKUYUHCJEZ-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CCN2C(NC(C2C1)=O)=N)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CCN2C(NC(C2C1)=O)=N)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl PPKQTKUYUHCJEZ-UHFFFAOYSA-N 0.000 description 1
- BXBNCVUOVXOYHO-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CCNCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CCNCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl BXBNCVUOVXOYHO-UHFFFAOYSA-N 0.000 description 1
- DVDBOEOOKYNGTM-UHFFFAOYSA-N C1(NCCCC1)C=C(/N1CCNCC1)NCC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCC1)C=C(/N1CCNCC1)NCC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl DVDBOEOOKYNGTM-UHFFFAOYSA-N 0.000 description 1
- IULIQGICROPJCC-BCJTWVECSA-N C1(NCCCC1)\C=C(/N(CC1=NC=CC=C1)CC1=CC=C(C=C1)F)\NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 Chemical compound C1(NCCCC1)\C=C(/N(CC1=NC=CC=C1)CC1=CC=C(C=C1)F)\NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 IULIQGICROPJCC-BCJTWVECSA-N 0.000 description 1
- BHMPFZUBYVWAPX-UHFFFAOYSA-N C1(NCCCCC1)C=C(/N1CCNCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C1(NCCCCC1)C=C(/N1CCNCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl BHMPFZUBYVWAPX-UHFFFAOYSA-N 0.000 description 1
- YRDKFDWQXPTILW-VEILYXNESA-N C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=C/N1C(C2)CCC2C1 Chemical compound C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=C/N1C(C2)CCC2C1 YRDKFDWQXPTILW-VEILYXNESA-N 0.000 description 1
- QKRNCGQHBUQTTM-BVFVYWQFSA-N C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCC1 Chemical compound C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCC1 QKRNCGQHBUQTTM-BVFVYWQFSA-N 0.000 description 1
- YTEWFZCSYNSRIB-PBDKAQRYSA-N C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCCC1 Chemical compound C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCCC1 YTEWFZCSYNSRIB-PBDKAQRYSA-N 0.000 description 1
- PDLCFUVLHASXLU-GEVKEYJPSA-N CC(C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)C Chemical compound CC(C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)C PDLCFUVLHASXLU-GEVKEYJPSA-N 0.000 description 1
- UZMWIDULSWTKKU-GYZAEMSSSA-N CC([C@]1(C[C@](C2)(C1(C)C)[H])[H])C2\N=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl Chemical compound CC([C@]1(C[C@](C2)(C1(C)C)[H])[H])C2\N=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl UZMWIDULSWTKKU-GYZAEMSSSA-N 0.000 description 1
- SSQVVXGMQPZZIA-IXCHTMLJSA-N CC1N(C[C@@H](NC1)C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound CC1N(C[C@@H](NC1)C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl SSQVVXGMQPZZIA-IXCHTMLJSA-N 0.000 description 1
- WSDHIRSASMFWEU-KEDRUTJZSA-N CCCC1CCCCC1\N=C(N1C[C@@H](C)N[C@@H](C)C1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 Chemical compound CCCC1CCCCC1\N=C(N1C[C@@H](C)N[C@@H](C)C1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 WSDHIRSASMFWEU-KEDRUTJZSA-N 0.000 description 1
- VZBNSHBEXKFQKM-QAAXHWMCSA-N CCCC1CCCCC1\N=C(N1C[C@H](C)NCC1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 Chemical compound CCCC1CCCCC1\N=C(N1C[C@H](C)NCC1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 VZBNSHBEXKFQKM-QAAXHWMCSA-N 0.000 description 1
- YXGMHUDCULSRLD-BUUPBASBSA-N CC[C@@H]1CCCC[C@H]1\N=C(N1C[C@@H](C)N[C@@H](C)C1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 Chemical compound CC[C@@H]1CCCC[C@H]1\N=C(N1C[C@@H](C)N[C@@H](C)C1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 YXGMHUDCULSRLD-BUUPBASBSA-N 0.000 description 1
- NRDIONMYKFXPOB-TYZIXWKHSA-N CC[C@H]1CN(CCN1)/C(=C\C2CCCN2)/NC3=CC=C(C=C3)C(=O)NCCC4=C(C=C(C=C4)Cl)Cl Chemical compound CC[C@H]1CN(CCN1)/C(=C\C2CCCN2)/NC3=CC=C(C=C3)C(=O)NCCC4=C(C=C(C=C4)Cl)Cl NRDIONMYKFXPOB-TYZIXWKHSA-N 0.000 description 1
- WDRRADZEYLHWGM-AMVUTOCUSA-N CSCC[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound CSCC[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl WDRRADZEYLHWGM-AMVUTOCUSA-N 0.000 description 1
- WWDGBVKQPQLVTH-PRIXLJELSA-N C[C@@H]1CN(C[C@H](N1)C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@@H]1CN(C[C@H](N1)C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl WWDGBVKQPQLVTH-PRIXLJELSA-N 0.000 description 1
- UJRBSAPXIFZQQF-XGLRFROISA-N C[C@H]1CN(CCN1)C(=C/C1NC=CCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NC=CCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl UJRBSAPXIFZQQF-XGLRFROISA-N 0.000 description 1
- FCJYBMZFIWJUTP-XNUZUHMRSA-N C[C@H]1CN(CCN1)C(=C/C1NCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl FCJYBMZFIWJUTP-XNUZUHMRSA-N 0.000 description 1
- CUJGCHBVRHEMLP-QHELBMECSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=C(C=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)C Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=C(C=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)C CUJGCHBVRHEMLP-QHELBMECSA-N 0.000 description 1
- WVQCRMBPVMMYDY-HSTJUUNISA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=C(C=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)OC Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=C(C=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)OC WVQCRMBPVMMYDY-HSTJUUNISA-N 0.000 description 1
- CKNUAQIXZOWAOT-YMXDCFFPSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC(=C(C=C1Cl)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)OC Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC(=C(C=C1Cl)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl)OC CKNUAQIXZOWAOT-YMXDCFFPSA-N 0.000 description 1
- AIJDCWJTBGVOOO-XGLRFROISA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl AIJDCWJTBGVOOO-XGLRFROISA-N 0.000 description 1
- UPEPYJQTDBEJGA-XGLRFROISA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)F)F Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)F)F UPEPYJQTDBEJGA-XGLRFROISA-N 0.000 description 1
- PEVPONZZSPLIDA-JINQPTGOSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=C(C=C1)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=C(C=C1)Cl PEVPONZZSPLIDA-JINQPTGOSA-N 0.000 description 1
- QBDMLZJQQAXSMG-JINQPTGOSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=C(C=C1)F Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=C(C=C1)F QBDMLZJQQAXSMG-JINQPTGOSA-N 0.000 description 1
- ZFRWVFYIBOKDJM-BWDMCYIDSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=CC=CC=C1 ZFRWVFYIBOKDJM-BWDMCYIDSA-N 0.000 description 1
- PFCSIBOKLCGDEN-BWDMCYIDSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC=1NC2=CC=CC=C2C1 Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC=1NC2=CC=CC=C2C1 PFCSIBOKLCGDEN-BWDMCYIDSA-N 0.000 description 1
- MSYDXDWHPUPCBE-JINQPTGOSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NCC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCC1)NCC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl MSYDXDWHPUPCBE-JINQPTGOSA-N 0.000 description 1
- UGVPHENFPFFALD-JINQPTGOSA-N C[C@H]1CN(CCN1)C(=C/C1NCCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/C1NCCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl UGVPHENFPFFALD-JINQPTGOSA-N 0.000 description 1
- LTEUPPPIPSIGBJ-QHELBMECSA-N C[C@H]1CN(CCN1)C(=C/CC1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1)C(=C/CC1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl LTEUPPPIPSIGBJ-QHELBMECSA-N 0.000 description 1
- RKRFINYEGTYJDM-NRFANRHFSA-N C[C@H]1CN(CCN1)C(Nc1ccc(cc1)C(=O)NCCc1ccc(F)cc1)=NC1Cc2ccccc2C1 Chemical compound C[C@H]1CN(CCN1)C(Nc1ccc(cc1)C(=O)NCCc1ccc(F)cc1)=NC1Cc2ccccc2C1 RKRFINYEGTYJDM-NRFANRHFSA-N 0.000 description 1
- QRIHJXNPGSJRGW-JINQPTGOSA-N C[C@H]1CN(CCN1C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(CCN1C)C(=C/C1NCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl QRIHJXNPGSJRGW-JINQPTGOSA-N 0.000 description 1
- STJJZRLULHHRKL-RRZWQVKKSA-N C[C@H]1CN(C[C@H](N1)C)C(=C/C1NCCCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl Chemical compound C[C@H]1CN(C[C@H](N1)C)C(=C/C1NCCCCCC1)NC1=CC=C(C=C1)C(=O)NCCC1=C(C=C(C=C1)Cl)Cl STJJZRLULHHRKL-RRZWQVKKSA-N 0.000 description 1
- HZLLUBHAFFUVRR-YSMPRRRNSA-N ClC1=CC(Cl)=CC=C1CCNC(=O)C(C=C1)=CC=C1N\C(N1C2CC(NC2)C1)=C\C1NCCCC1 Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C(C=C1)=CC=C1N\C(N1C2CC(NC2)C1)=C\C1NCCCC1 HZLLUBHAFFUVRR-YSMPRRRNSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UZMWIDULSWTKKU-FBLYZMNKSA-N N(/[C@@H]1[C@@H](C)[C@]2(C[C@](C1)(C2(C)C)[H])[H])=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl Chemical compound N(/[C@@H]1[C@@H](C)[C@]2(C[C@](C1)(C2(C)C)[H])[H])=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl UZMWIDULSWTKKU-FBLYZMNKSA-N 0.000 description 1
- UZMWIDULSWTKKU-LELJEFGFSA-N N(/[C@H]1[C@H](C)[C@@]2(C[C@@](C1)(C2(C)C)[H])[H])=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl Chemical compound N(/[C@H]1[C@H](C)[C@@]2(C[C@@](C1)(C2(C)C)[H])[H])=C(N1C[C@H](C)NCC1)/NC(C=C1)=CC=C1C(=O)NCCC1=CC=C(Cl)C=C1Cl UZMWIDULSWTKKU-LELJEFGFSA-N 0.000 description 1
- CNYGJUDGEDSWTQ-QZHYJAGHSA-N N-[2-(2,4-dichlorophenyl)ethyl]-4-[[C-(3,5-dimethylpiperazin-1-yl)-N-[(1R,2R)-2-methylcycloheptyl]carbonimidoyl]amino]benzamide Chemical compound C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCCC1 CNYGJUDGEDSWTQ-QZHYJAGHSA-N 0.000 description 1
- VDCBAUXICMHAOR-VHKJGQLFSA-N N-[2-(2,4-dichlorophenyl)ethyl]-4-[[C-(3,5-dimethylpiperazin-1-yl)-N-[(1R,2R)-2-methylcyclohexyl]carbonimidoyl]amino]benzamide Chemical compound C1C(C)NC(C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N\[C@H]1[C@H](C)CCCC1 VDCBAUXICMHAOR-VHKJGQLFSA-N 0.000 description 1
- JDALQHJLLLZLSL-IMSLXYDMSA-N N-[2-(2,4-dichlorophenyl)ethyl]-4-[[C-[(3S)-3-methylpiperazin-1-yl]-N-(4-phenylcyclohexyl)carbonimidoyl]amino]benzamide Chemical compound C1CN[C@@H](C)CN1C(\NC=1C=CC(=CC=1)C(=O)NCCC=1C(=CC(Cl)=CC=1)Cl)=N/C1CCC(C=2C=CC=CC=2)CC1 JDALQHJLLLZLSL-IMSLXYDMSA-N 0.000 description 1
- AIOYHECSCZDWOP-NRMJFJNESA-N N-[2-(2,4-dichlorophenyl)ethyl]-4-[[C-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-N-(3,3,5-trimethylcyclohexyl)carbonimidoyl]amino]benzamide Chemical compound C1C(C)(C)CC(C)CC1\N=C(N1C[C@@H](C)N[C@@H](C)C1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 AIOYHECSCZDWOP-NRMJFJNESA-N 0.000 description 1
- OSRNFISLLNLGLB-VIHQBZHPSA-N N-[2-(2,4-dichlorophenyl)ethyl]-4-[[N-(4-methylcyclohexyl)-C-[(3S)-3-methylpiperazin-1-yl]carbonimidoyl]amino]benzamide Chemical compound C1CC(C)CCC1\N=C(N1C[C@H](C)NCC1)\NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 OSRNFISLLNLGLB-VIHQBZHPSA-N 0.000 description 1
- HEELVTUFYFNRBT-QHCPKHFHSA-N N-[2-(4-methoxyphenyl)ethyl]-4-[[C-[(3S)-3-methylpiperazin-1-yl]-N-(2-propan-2-ylphenyl)carbonimidoyl]amino]benzamide Chemical compound C[C@H]1CN(CCN1)\C(=N\C1=C(C=CC=C1)C(C)C)\NC1=CC=C(C=C1)C(=O)NCCC1=CC=C(C=C1)OC HEELVTUFYFNRBT-QHCPKHFHSA-N 0.000 description 1
- 241000750042 Vini Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- WGBOHERIFRJILR-CMAULLTDSA-N n-[2-(2,4-dichlorophenyl)ethyl]-4-[[n-(3-methylcyclohexyl)-c-[(3s)-3-methylpiperazin-1-yl]carbonimidoyl]amino]benzamide Chemical compound C1C(C)CCCC1\N=C(N1C[C@H](C)NCC1)/NC1=CC=C(C(=O)NCCC=2C(=CC(Cl)=CC=2)Cl)C=C1 WGBOHERIFRJILR-CMAULLTDSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23056500P | 2000-08-31 | 2000-08-31 | |
| US24557900P | 2000-11-06 | 2000-11-06 | |
| PCT/US2001/027206 WO2002018327A2 (en) | 2000-08-31 | 2001-08-31 | Guanidinobenzamides as mc4-r agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004508304A JP2004508304A (ja) | 2004-03-18 |
| JP2004508304A5 true JP2004508304A5 (OSRAM) | 2008-06-26 |
| JP4166567B2 JP4166567B2 (ja) | 2008-10-15 |
Family
ID=26924350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002523445A Expired - Fee Related JP4166567B2 (ja) | 2000-08-31 | 2001-08-31 | 新規グアニジノベンズアミド |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6638927B2 (OSRAM) |
| EP (1) | EP1409468B9 (OSRAM) |
| JP (1) | JP4166567B2 (OSRAM) |
| KR (1) | KR20030034163A (OSRAM) |
| CN (1) | CN1659156A (OSRAM) |
| AP (1) | AP2003002755A0 (OSRAM) |
| AT (1) | ATE414067T1 (OSRAM) |
| AU (2) | AU8860401A (OSRAM) |
| BG (1) | BG107639A (OSRAM) |
| BR (1) | BR0113643A (OSRAM) |
| CA (1) | CA2420694C (OSRAM) |
| CZ (1) | CZ2003882A3 (OSRAM) |
| DE (1) | DE60136571D1 (OSRAM) |
| DZ (1) | DZ3415A1 (OSRAM) |
| EA (1) | EA200300323A1 (OSRAM) |
| ES (1) | ES2316467T3 (OSRAM) |
| HU (1) | HUP0302067A2 (OSRAM) |
| IL (1) | IL154604A0 (OSRAM) |
| MA (1) | MA26948A1 (OSRAM) |
| MX (1) | MXPA03001813A (OSRAM) |
| NO (1) | NO20030929L (OSRAM) |
| NZ (1) | NZ524897A (OSRAM) |
| PL (1) | PL360698A1 (OSRAM) |
| PT (1) | PT1409468E (OSRAM) |
| SI (1) | SI21267A (OSRAM) |
| SK (1) | SK3832003A3 (OSRAM) |
| WO (1) | WO2002018327A2 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2278016T3 (es) | 2001-04-09 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r). |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| AU2002345664C1 (en) | 2001-06-11 | 2008-03-06 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US20030195187A1 (en) * | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
| US20030207814A1 (en) * | 2002-02-04 | 2003-11-06 | Chiron Corporation | Novel guanidinyl derivatives |
| US20050124652A1 (en) * | 2002-02-04 | 2005-06-09 | Rustum Boyce | Guanidino compounds |
| AU2003219914A1 (en) * | 2002-02-25 | 2003-09-09 | Chiron Corporation | Intranasal administration of mc4-r agonists |
| CA2486966A1 (en) | 2002-05-23 | 2003-12-04 | Chiron Corporation | Substituted quinazolinone compounds |
| US7125904B2 (en) * | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
| AU2003297629A1 (en) * | 2002-12-04 | 2004-06-23 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| US7625909B2 (en) * | 2003-05-23 | 2009-12-01 | Novartis Vaccines And Diagnostics, Inc. | Substituted quinazolinone compounds |
| JP2005306839A (ja) * | 2003-08-29 | 2005-11-04 | Takeda Chem Ind Ltd | 二環性ピペラジン化合物およびその用途 |
| EP1661898A4 (en) * | 2003-08-29 | 2009-04-15 | Takeda Pharmaceutical | BICYCLIC PIPERAZINE COMPOUND AND ITS USE |
| MXPA06005736A (es) * | 2003-11-19 | 2006-12-14 | Chiron Corp | Compuestos de quinazolinona con bioacumulacion reducida. |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| US7795448B2 (en) | 2004-05-06 | 2010-09-14 | Cytokinetics, Incorporated | Imidazoyl-benzamide anti-cancer agents |
| US7504413B2 (en) | 2004-05-06 | 2009-03-17 | Cytokinetics, Inc. | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases |
| US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| MX2007005306A (es) | 2004-11-04 | 2007-06-11 | Xenoport Inc | Formas de dosis oral de liberacion sostenida de la prodroga gabapentina. |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| EP1917244A2 (de) | 2005-08-24 | 2008-05-07 | Abbott GmbH & Co. KG | Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| MX2008015454A (es) | 2006-06-09 | 2009-01-30 | Action Pharma As | Derivados de fenil-pirrol-aminoguanidina. |
| GB0624987D0 (en) | 2006-12-14 | 2007-01-24 | Acure Pharma Ab | Novel aminoguanidines as melanocortin receptor ligands |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| EP2358200A4 (en) | 2008-11-17 | 2012-05-16 | Merck Sharp & Dohme | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| CA2825098C (en) | 2011-01-27 | 2020-03-10 | Universite De Montreal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| SI3773558T1 (sl) | 2019-05-10 | 2022-11-30 | Synact Pharma Aps | Kombinirano zdravljenje artritične bolezni |
| CA3220753A1 (en) | 2021-06-21 | 2022-12-29 | Synact Pharma Aps | Salts of phenyl pyrrole aminoguanidine and polymorphs of phenyl pyrrole aminoguanidinium salts |
| CN115850117B (zh) * | 2022-11-15 | 2024-06-04 | 黎明化工研究设计院有限责任公司 | 一种制备1,4-环己烷二异氰酸酯的方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3177218A (en) | 1962-01-17 | 1965-04-06 | Monsanto Chemicals | Methylene-bis(2-guanidino-4-methylquinazoline) |
| DE2623846A1 (de) | 1976-05-28 | 1977-12-15 | Hoechst Ag | 4-chinazolinyl-guanidine und verfahren zu ihrer herstellung |
| US4287341A (en) | 1979-11-01 | 1981-09-01 | Pfizer Inc. | Alkoxy-substituted-6-chloro-quinazoline-2,4-diones |
| DE3270716D1 (en) | 1981-02-27 | 1986-05-28 | Ici Plc | Guanidino-substituted heterocyclic derivatives having histamine h-2 antagonist activity |
| DE3267110D1 (de) | 1981-05-18 | 1985-12-05 | Ici Plc | Amidine derivatives |
| US4921939A (en) * | 1985-03-19 | 1990-05-01 | Universite Claude Bernard -Lyon 1 | Sweetening agents |
| JPS6229566A (ja) | 1985-07-30 | 1987-02-07 | Taiyo Yakuhin Kogyo Kk | 新規グアニジノメチル安息香酸誘導体 |
| US4948901A (en) | 1988-05-24 | 1990-08-14 | Pfizer Inc. | Benzamide protease inhibitors |
| US4874864A (en) | 1988-05-24 | 1989-10-17 | Pfizer Inc. | Benzamide protease inhibitors |
| US4948891A (en) | 1988-05-24 | 1990-08-14 | Pfizer Inc. | Benzamide protease inhibitors |
| JPH0276880A (ja) | 1988-06-16 | 1990-03-16 | Sankyo Co Ltd | 悪液質改善治療剤 |
| GB8926512D0 (en) | 1989-11-23 | 1990-01-10 | Pfizer Ltd | Therapeutic agents |
| CA2032420A1 (en) | 1989-12-22 | 1991-06-23 | Akira Okuyama | Guanidinobenzene derivatives |
| US5124328A (en) | 1990-10-11 | 1992-06-23 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| DE69418601T2 (de) | 1993-03-23 | 1999-09-30 | Astra Aktiebolag, Soedertaelje | Guanidinderivate mit therapeutischer wirkung |
| CZ29996A3 (en) | 1993-08-12 | 1996-09-11 | Astra Ab | Amidine derivatives with activities of nitrogen oxide sythetase |
| US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
| US5599984A (en) | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
| US5637439A (en) | 1994-11-07 | 1997-06-10 | Mitsubishi Paper Mills Ltd. | Photographic silver halide photosensitive material and method for developing the same |
| AU4534596A (en) | 1995-02-09 | 1996-08-27 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| DE19544685A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE19544687A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| CA2250698A1 (en) | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Para-substituted phenylpropanoic acid derivatives as integrin antagonists |
| US5889025A (en) | 1996-05-06 | 1999-03-30 | Reddy's Research Foundation | Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| US6127343A (en) | 1996-05-14 | 2000-10-03 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
| CA2268051A1 (en) | 1996-08-23 | 1998-02-26 | Alanex Corporation | Neuropeptide-y ligands |
| ZA979701B (en) | 1996-10-31 | 1998-05-21 | Novo Nordisk As Novo Nordisk A | Constrained somatostatin agonists and antagonists.Constrained somatostatin agonists and antagonists. |
| KR20000069131A (ko) | 1996-11-25 | 2000-11-25 | 데이비드 엠 모이어 | 알파-2 아드레날린수용체 아고니스트로서 유용한 구아니디닐 헤테로사이클 화합물 |
| EP0981526B1 (en) | 1997-05-02 | 2004-02-25 | Dr. Reddy's Laboratories Ltd. | Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| DE19831710A1 (de) * | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| FR2784678B1 (fr) | 1998-09-23 | 2002-11-29 | Sod Conseils Rech Applic | Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| JP2002536411A (ja) | 1999-02-09 | 2002-10-29 | ブリストル−マイヤーズ スクイブ カンパニー | Ｘａ因子のラクタム系阻害剤および方法 |
| CA2377369A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| MXPA02001160A (es) * | 1999-08-04 | 2002-07-02 | Millennium Pharm Inc | Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos. |
| GB0002059D0 (en) | 2000-01-28 | 2000-03-22 | Melacure Therapeutics Ab | Novel aromatic amines |
| EP1254114A2 (en) | 2000-01-28 | 2002-11-06 | Melacure Therapeutics AB | Melanocortin receptor agonists and antagonists |
| AU2001228681A1 (en) | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
| JP2003528088A (ja) | 2000-03-23 | 2003-09-24 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| JP2003527444A (ja) | 2000-03-23 | 2003-09-16 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体 |
| GB0102668D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| ES2278016T3 (es) | 2001-04-09 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r). |
| CA2486966A1 (en) | 2002-05-23 | 2003-12-04 | Chiron Corporation | Substituted quinazolinone compounds |
-
2001
- 2001-08-21 DZ DZ013415A patent/DZ3415A1/fr active
- 2001-08-31 PT PT01968352T patent/PT1409468E/pt unknown
- 2001-08-31 SK SK383-2003A patent/SK3832003A3/sk unknown
- 2001-08-31 AU AU8860401A patent/AU8860401A/xx active Pending
- 2001-08-31 DE DE60136571T patent/DE60136571D1/de not_active Expired - Lifetime
- 2001-08-31 MX MXPA03001813A patent/MXPA03001813A/es active IP Right Grant
- 2001-08-31 IL IL15460401A patent/IL154604A0/xx unknown
- 2001-08-31 KR KR10-2003-7003017A patent/KR20030034163A/ko not_active Withdrawn
- 2001-08-31 SI SI200120058A patent/SI21267A/sl not_active IP Right Cessation
- 2001-08-31 CA CA002420694A patent/CA2420694C/en not_active Expired - Fee Related
- 2001-08-31 AP APAP/P/2003/002755A patent/AP2003002755A0/en unknown
- 2001-08-31 JP JP2002523445A patent/JP4166567B2/ja not_active Expired - Fee Related
- 2001-08-31 HU HU0302067A patent/HUP0302067A2/hu unknown
- 2001-08-31 NZ NZ524897A patent/NZ524897A/en unknown
- 2001-08-31 ES ES01968352T patent/ES2316467T3/es not_active Expired - Lifetime
- 2001-08-31 US US09/945,384 patent/US6638927B2/en not_active Expired - Fee Related
- 2001-08-31 EA EA200300323A patent/EA200300323A1/ru unknown
- 2001-08-31 PL PL36069801A patent/PL360698A1/xx not_active Application Discontinuation
- 2001-08-31 AU AU2001288604A patent/AU2001288604B2/en not_active Ceased
- 2001-08-31 AT AT01968352T patent/ATE414067T1/de not_active IP Right Cessation
- 2001-08-31 EP EP01968352A patent/EP1409468B9/en not_active Expired - Lifetime
- 2001-08-31 WO PCT/US2001/027206 patent/WO2002018327A2/en not_active Ceased
- 2001-08-31 CZ CZ2003882A patent/CZ2003882A3/cs unknown
- 2001-08-31 BR BR0113643-7A patent/BR0113643A/pt not_active IP Right Cessation
- 2001-08-31 CN CN018177182A patent/CN1659156A/zh active Pending
-
2003
- 2003-02-27 NO NO20030929A patent/NO20030929L/no not_active Application Discontinuation
- 2003-02-28 MA MA27062A patent/MA26948A1/fr unknown
- 2003-03-04 US US10/379,397 patent/US6995269B2/en not_active Expired - Fee Related
- 2003-03-18 BG BG107639A patent/BG107639A/bg unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004508304A5 (OSRAM) | ||
| FI104069B (fi) | Menetelmä terapeuttisesti käyttökelpoisten 3-(fenyyli- tai sykloalkyyli)-3-hydroksi-1-fenyylisulfonyyli-2-indoliinikarboksamidijohdannaisten valmistamiseksi | |
| CA2352554C (en) | Substituted benzimidazoles and their use as parp inhibitors | |
| ES2258331T3 (es) | Compuestos heterociclicos y procedimientos de tratamiento de insuficiencia cardiaca y otros trastornos. | |
| TWI248435B (en) | Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions | |
| AU2002349773B2 (en) | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivatives or salts thereof | |
| JP2009528354A5 (OSRAM) | ||
| JP2006504761A5 (OSRAM) | ||
| CA2436526A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| JP2012509940A5 (OSRAM) | ||
| JP2008502700A5 (OSRAM) | ||
| JP2010505881A5 (OSRAM) | ||
| JP2007507529A (ja) | 複素環式アミドおよびスルホンアミド | |
| JP2006519258A5 (OSRAM) | ||
| HRP20120069T1 (hr) | Derivati 5,6-bisaril-2-piridinkarboksamida, njihovo dobivanje i njihova upotreba u terapiji kao antagonista receptora urotenzina ii | |
| JP2007519695A5 (OSRAM) | ||
| JPH08508738A (ja) | ５−ｈｔ１ａ及び／又は５−ｈｔ２リガンドとしてのインドール誘導体 | |
| JP2010501587A5 (OSRAM) | ||
| JP2004523490A5 (OSRAM) | ||
| RU2004135567A (ru) | Основные непептидные антагонисты брадикинина и их фармацевтические композиции | |
| JP2013509376A5 (OSRAM) | ||
| JP2004525173A5 (OSRAM) | ||
| RU2007127864A (ru) | Производные n-[(4, 5-дифенил-3-алкил-2-тиенил)метил]амина (амид, сульфонамид, карбамат и карбамид) в качестве антагонистов рецепторов св1 каннабиноидов | |
| US20060111364A1 (en) | Cathepsin cysteine protease inhibitors and their use | |
| JP2005504093A5 (OSRAM) |